Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder

Leanne Tamm, Kathlene Trello-Rishel, Paula Riggs, Paul A. Nakonezny, Michelle Acosta, Genie Bailey, Theresa Winhusen

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Attention-Deficit/Hyperactivity Disorder (ADHD) frequently co-occurs with substance use disorder (SUD) and is associated with poor substance-use treatment outcomes. A trial evaluating osmotic-release oral system methylphenidate (OROS-MPH) for adolescents with ADHD and SUD, concurrently receiving behavioral therapy, revealed inconsistent medication effects on ADHD or SUD. Clinical care for this population would be advanced by knowledge of treatment outcome predictors. Data from the randomized placebo-controlled trial (n = 299) were analyzed. Significant treatment predictors included: 1) Substance use severity, associated with poorer ADHD and SUD outcomes, 2) ADHD severity, associated with better ADHD and SUD outcomes, 3) comorbid conduct disorder, associated with poorer ADHD outcomes, and 4) court-mandated status, associated with better SUD outcomes but poorer treatment completion. An interaction effect showed that OROS-MPH improved SUD outcomes in adolescents with comorbid conduct disorder compared to placebo. While severe SUD may require more intensive psychosocial treatment, OROS-MPH may improve substance treatment outcomes in adolescents with co-morbid attention and conduct problems.

Original languageEnglish (US)
Pages (from-to)224-230
Number of pages7
JournalJournal of Substance Abuse Treatment
Volume44
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Attention Deficit Disorder with Hyperactivity
Substance-Related Disorders
Methylphenidate
Conduct Disorder
Therapeutics
Placebos
Randomized Controlled Trials
Population

Keywords

  • Attention-Deficit/Hyperactivity Disorder
  • Conduct disorder
  • OROS-MPH
  • Predictors of treatment response
  • Substance Use Disorder

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology
  • Phychiatric Mental Health
  • Medicine (miscellaneous)

Cite this

Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder. / Tamm, Leanne; Trello-Rishel, Kathlene; Riggs, Paula; Nakonezny, Paul A.; Acosta, Michelle; Bailey, Genie; Winhusen, Theresa.

In: Journal of Substance Abuse Treatment, Vol. 44, No. 2, 02.2013, p. 224-230.

Research output: Contribution to journalArticle

@article{ef48449b38f741ee80a1c7513fc73668,
title = "Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder",
abstract = "Attention-Deficit/Hyperactivity Disorder (ADHD) frequently co-occurs with substance use disorder (SUD) and is associated with poor substance-use treatment outcomes. A trial evaluating osmotic-release oral system methylphenidate (OROS-MPH) for adolescents with ADHD and SUD, concurrently receiving behavioral therapy, revealed inconsistent medication effects on ADHD or SUD. Clinical care for this population would be advanced by knowledge of treatment outcome predictors. Data from the randomized placebo-controlled trial (n = 299) were analyzed. Significant treatment predictors included: 1) Substance use severity, associated with poorer ADHD and SUD outcomes, 2) ADHD severity, associated with better ADHD and SUD outcomes, 3) comorbid conduct disorder, associated with poorer ADHD outcomes, and 4) court-mandated status, associated with better SUD outcomes but poorer treatment completion. An interaction effect showed that OROS-MPH improved SUD outcomes in adolescents with comorbid conduct disorder compared to placebo. While severe SUD may require more intensive psychosocial treatment, OROS-MPH may improve substance treatment outcomes in adolescents with co-morbid attention and conduct problems.",
keywords = "Attention-Deficit/Hyperactivity Disorder, Conduct disorder, OROS-MPH, Predictors of treatment response, Substance Use Disorder",
author = "Leanne Tamm and Kathlene Trello-Rishel and Paula Riggs and Nakonezny, {Paul A.} and Michelle Acosta and Genie Bailey and Theresa Winhusen",
year = "2013",
month = "2",
doi = "10.1016/j.jsat.2012.07.001",
language = "English (US)",
volume = "44",
pages = "224--230",
journal = "Journal of Substance Abuse Treatment",
issn = "0740-5472",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder

AU - Tamm, Leanne

AU - Trello-Rishel, Kathlene

AU - Riggs, Paula

AU - Nakonezny, Paul A.

AU - Acosta, Michelle

AU - Bailey, Genie

AU - Winhusen, Theresa

PY - 2013/2

Y1 - 2013/2

N2 - Attention-Deficit/Hyperactivity Disorder (ADHD) frequently co-occurs with substance use disorder (SUD) and is associated with poor substance-use treatment outcomes. A trial evaluating osmotic-release oral system methylphenidate (OROS-MPH) for adolescents with ADHD and SUD, concurrently receiving behavioral therapy, revealed inconsistent medication effects on ADHD or SUD. Clinical care for this population would be advanced by knowledge of treatment outcome predictors. Data from the randomized placebo-controlled trial (n = 299) were analyzed. Significant treatment predictors included: 1) Substance use severity, associated with poorer ADHD and SUD outcomes, 2) ADHD severity, associated with better ADHD and SUD outcomes, 3) comorbid conduct disorder, associated with poorer ADHD outcomes, and 4) court-mandated status, associated with better SUD outcomes but poorer treatment completion. An interaction effect showed that OROS-MPH improved SUD outcomes in adolescents with comorbid conduct disorder compared to placebo. While severe SUD may require more intensive psychosocial treatment, OROS-MPH may improve substance treatment outcomes in adolescents with co-morbid attention and conduct problems.

AB - Attention-Deficit/Hyperactivity Disorder (ADHD) frequently co-occurs with substance use disorder (SUD) and is associated with poor substance-use treatment outcomes. A trial evaluating osmotic-release oral system methylphenidate (OROS-MPH) for adolescents with ADHD and SUD, concurrently receiving behavioral therapy, revealed inconsistent medication effects on ADHD or SUD. Clinical care for this population would be advanced by knowledge of treatment outcome predictors. Data from the randomized placebo-controlled trial (n = 299) were analyzed. Significant treatment predictors included: 1) Substance use severity, associated with poorer ADHD and SUD outcomes, 2) ADHD severity, associated with better ADHD and SUD outcomes, 3) comorbid conduct disorder, associated with poorer ADHD outcomes, and 4) court-mandated status, associated with better SUD outcomes but poorer treatment completion. An interaction effect showed that OROS-MPH improved SUD outcomes in adolescents with comorbid conduct disorder compared to placebo. While severe SUD may require more intensive psychosocial treatment, OROS-MPH may improve substance treatment outcomes in adolescents with co-morbid attention and conduct problems.

KW - Attention-Deficit/Hyperactivity Disorder

KW - Conduct disorder

KW - OROS-MPH

KW - Predictors of treatment response

KW - Substance Use Disorder

UR - http://www.scopus.com/inward/record.url?scp=84870691140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870691140&partnerID=8YFLogxK

U2 - 10.1016/j.jsat.2012.07.001

DO - 10.1016/j.jsat.2012.07.001

M3 - Article

VL - 44

SP - 224

EP - 230

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

SN - 0740-5472

IS - 2

ER -